SELLAS REGAL Trial Shows Stronger Survival Trends; Pre-BLA FDA Meeting Planned
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS Life Sciences' CEO announced that the pivotal Phase 3 REGAL trial is exhibiting stronger-than-expected survival trends. The company plans to hold a pre-BLA FDA meeting and potentially file for approval. This follows the May 12th 10-Q and 8-K filings, which indicated the REGAL trial was nearing final data analysis. Positive survival trends in a late-stage trial are highly material for a biotech company, signaling a significant step towards potential drug approval and commercialization. The planned pre-BLA meeting underscores the company's confidence in the data.
At the time of this announcement, SLS was trading at $8.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $1.39 to $9.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.